IMV Leadership to Participate in Upcoming Investor and Business Development Conferences
31 May 2018 - 6:35AM
IMV Inc. (TSX:IMV) (OTCQX:IMMVD), a clinical stage immuno-oncology
company, today announced details on upcoming industry presentations
that the company’s leadership will be making at the 4th Annual
Immuno-Oncology BD&L and Investment (IOBDLI) Forum and the
International Cancer Cluster Showcase (ICCS).
Chief Executive Officer Frederic Ors will join in the IOBDLI
Forum, which is taking place on June 1, 2018, at the Waldorf
Astoria Hotel in Chicago. Mr. Ors will present a corporate update,
and participate in a panel discussion on recent industry
innovations in targeted cancer immunotherapies.
In addition, Joseph Sullivan, IMV’s Senior Vice President of
Business Development, will present an update on the Company’s
progress and corporate strategy at the ICCS on June 4, 2018, during
the 2018 BIO International Convention, taking place at the Boston
Convention Center.
Details for Mr. Ors’ IOBDLI events are as follows:
Plenary Session Panel Discussion
- Title: Cancer Vaccines and Neo Antigens Evaluating Latest
Progress Panel
- Date: June 1, 2018
- Time: 11:20 a.m. – 12:00 p.m. CT
- Location: Waldorf Astoria Hotel
IMV Corporate Presentation:
- Date: June 1, 2018
- Time: 3:20 p.m. – 3:40 p.m. CT
- Presentation Track D
- Location: Waldorf Astoria Hotel, Sinclair Ballroom
Details for Mr. Sullivan’s ICCS presentation include:
- Date: June 4, 2018
- Time: 12:30 p.m. ET
- Location: Boston Convention Center, Level 2, Rooms 256 and
258A
About the Conferences
Immuno-Oncology BD&L and Investment (IOBDLI)
Forum Taking place on the first day of ASCO, the 4th
Annual Immuno-Oncology BD&L and Investment Forum is designed to
bring together thought leaders from cancer research institutes,
patient advocacy groups, pharma and biotech to facilitate
partnering, funding and investment. Conference organizers expect
approximately 200 delegates and over 20 presentations by listed and
private biotechnology companies seeking licensing and
investment.
International Cancer Cluster Showcase (ICCS)
2018The 7th International Cancer Cluster Showcase, taking
place during the annual BIO International Convention in Boston,
features 200+ representatives of the
international oncology community. Participants
from leading North American and European biotech companies present
innovations and latest R&D activities in compact four minute
presentations.
About IMVIMV Inc., formerly Immunovaccine
Inc., is a clinical stage biopharmaceutical company dedicated to
making immunotherapy more effective, more broadly applicable, and
more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently conducting three clinical studies with Incyte and
Merck assessing DPX-Survivac as a combination therapy in ovarian
cancer and diffuse large B-cell lymphoma. Connect
at www.imv-inc.com.
Contacts for IMV:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024